ArticlePharmaceutics2023

Comparative Safety Analysis of Empagliflozin in Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease versus Normal Kidney Function: A Nationwide Cohort Study in Korea.

Ha Young Jang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.